Jeff served on the Novartis Group Executive Committee from 2008 to 2016, first as Division Head and CEO of Sandoz (2008-2014), Novartis’s $10 billion generic pharmaceuticals and biosimilars subsidiary, and then as Division Head and CEO of Alcon (2014-2016), Novartis’s $10 billion eye care subsidiary. Prior to this, he was Head of Emerging Markets at Novartis Pharmaceuticals for the Middle East, Africa, Asia and CIS, after serving as Vice President and Head of Western & Eastern Europe for Novartis Vaccines.
In both of his divisional CEO roles, Jeff was responsible for leading over 25,000 associates globally across more than 160 countries and had primary line leadership and management responsibility for all Sandoz and Alcon functions including Commercial, R&D, Manufacturing, Finance, HR, Legal, Quality, IP, Business Development and M&A, Strategy, Regulatory, and Market Access.
Sandoz is the second-largest generic pharmaceuticals company globally. During over five years that Jeff led Sandoz, its sales grew by over $1.7 billion to $9.2 billion in 2013. During this time, Sandoz became the global leader in biosimilars and differentiated generics, with biosimilar sales quintupling while Sandoz attained #1 positions globally in generic dermatologics, ophthalmics, and injectables.
In early 2014, Jeff was appointed to lead Alcon, the largest eye care and ophthalmology company globally, which Novartis acquired for $52 billion in 2011. During nearly two years at Alcon, Jeff and his team significantly strengthened Alcon’s leadership talent, accelerated Alcon’s innovation in its surgical and pharmaceuticals businesses, and completed over 10 business development, licensing, and acquisition deals to bolster future growth. Jeff stepped down from his Alcon role when Novartis decided to restructure Alcon by integrating its $3.6 billion ophthalmic pharmaceutical business into Novartis Pharma.
Before joining Novartis, Jeff was Senior Director of Strategic Planning and Business Development at Gap Inc., where he led growth, licensing, and European expansion efforts for one of its apparel divisions. Prior to this he was an Engagement Manager at McKinsey & Company in San Francisco. Jeff has also worked in emerging markets private equity in South Africa and in Washington, D.C.
Jeff holds an MBA from Harvard University and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was awarded the John W. Watzek Fellowship. He received his bachelor’s degree in international relations, magna cum laude and Phi Beta Kappa, from Carleton College.
Jeff served on the Board of Directors for AdvaMed, the medical device industry association, from 2014 to 2016, and is a member of the Young President’s Organization (YPO). He was twice named to Fortune’s “40 under 40” list of up-and-coming leaders. He has lived in seven countries on four continents and is married with two daughters. He enjoys running, soccer, live music, meditation, and traveling with family.